NovaVive Inc., an animal health immunobiology company, announced that data from a study with its immunotherapy for the treatment of equine endometritis—Settle—was presented January 17 2020, at the 10 Leipzig Veterinary Workshop on Equine Reproduction in Leipzig, Germany.
Dr. Mats Troedsson, a professor at the Maxwell H. Gluck Equine Research Center, University of Kentucky, presented data from a study assessing the effect of Settle on histological involution, cell-mediated immunity of the uterus, and clinical endpoints associated with involution.
Uterine involution is a natural occurrence in the postpartum mare, characterized by expulsion of fetal membranes and contraction of the uterus, cervix and broad ligaments. For maximum reproductive efficiency, a broodmare must produce a foal every year. To retain this schedule, the mare must be bred at the “foal heat” (first postpartum estrus). If uterine involution occurs efficiently, foal heat breeding is more likely to be successful.
In this study, 16 postpartum mares were divided into three treatment groups. Group 1 received two doses of Settle, one week apart, by IV injection; group 2 received one dose of Settle every three days until ovulation was detected; and group 3 received two doses of lactated Ringers solution, one week apart. The mares’ reproductive tracts were assessed every 72 hours and cytology and bacterial cultures were undertaken.
Researchers concluded that Settle might improve postpartum clearance of bacteria in the uterus by increasing a variety of pro-inflammatory markers, contributing to an increase in antigen production and leading to rapid bacterial clearance. Based on their findings, the researchers recommend that Settle be administered in a two-dose series for maximum effect—one day postpartum and one week postpartum—to assist with the elimination of bacteria that might impede future fertility on the foal heat estrus cycle.
In another clinical study (Fumuso et al. 2003), mares bred at foal heat and treated with Settle had a 65% pregnancy rate as compared to a 24% pregnancy rate for mares bred at foal heat and treated with a placebo.
Settle is manufactured using the NovaVive Mycobacterium cell wall fraction (MCWF) technology. It is approved in the U.S.A., Australia and New Zealand as an aid in the treatment of equine endometritis caused by Streptococcus zooepidemicus, the hardest-to-treat cause of the disease. When administered by IV injection or intrauterine (IU) infusion, Settle stimulates the mare’s immune system to fight the infection.
About NovaVive Inc.
NovaVive is a private company founded in July, 2014. The Company has an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology with five regulator-approved products in the U.S. One formulation has been developed as an anticancer therapy in dogs and horses. Other formulations have demonstrated the capability of reducing the reliance on antibiotics in the treatment of bacterial diseases of horses and cattle or effectively treating viral equine respiratory disease. The Company’s development plan is to identify additional livestock and companion animal diseases that might be effectively treated with its immunotherapeutic technology platform.
For more information about Settle, please review this presentation.
For more information about the Company, please visit www.NovaVive.ca